In December 2020, Suzhou-based Sinovent completed Pre-IPO financing of hundreds of millions of yuan, led by Oceanpine Capital, with participation from China Development Capital, Jiuyou Capital, Fengyi Yuanda Equity Investment, ABC International, DeGuan Capital, and other well-known investors. StartPointAdvisors acted as the exclusive financial consultant of this round.
The funds raised in this round will be used for production base construction and clinical trials at home and abroad, and the launch of new products to benefit patients.
Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation for significant unmet clinical needs. The company owns several intellectual property rights globally. Sinovent is centered around global standard excellence through its advanced biotechnology platform to develop and promote advanced treatment methods to solve worldwide healthcare problems.
Sinovent focuses on developing the new generation of best-in-class and first-in-class products. Its R&D projects cover the indications of cancer, antibiotics, autoimmune diseases, and metabolic diseases. So far, five products have entered the clinical stage domestically and abroad, and three products have entered the IND-Enabling stage.
About Oceanpine Capital
Oceanpine Capital is an institutional growth equity investment company formed by seasoned entrepreneurs and sophisticated investors. We are rooted in China with 20 years of in-depth industry operational and business building experience. Our profound industrial and business partners' (CEO club) network not only enables us to originate true proprietary companies with visible customer and revenues, but also provides tremendous value-added services to our portfolio companies and therefore foster their further growth. We invest in DeepTech, innovative growth companies in both TMT and healthcare sectors that are the driving force of the future economy in the New Norm. We believe in long term compounding value investing and provide value-added services to our companies by offering strategic resource and operational support.
About CDIB Capital
CDIB Capital operates as the overseas investment arm of China Development Financial (CDF), one of the largest and longest-standing merchant banking groups in Asia with approx. US$25 billion in assets. CDIB Capital is headquartered in Hong Kong, with principal offices in Taipei, Shanghai, Seoul and New York.
Source: Sinovent
